Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 16 years or older at the time of joining the trial
- People who are able to understand and sign a written consent form
- People who have been diagnosed with a type of Large B-cell non-Hodgkin's lymphoma (a blood cancer) that has been confirmed by a tissue sample, and who have not yet received any treatment for it
- People diagnosed with one of many specific subtypes of Large B-cell lymphoma, including but not limited to: Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma with certain genetic changes (MYC, BCL2, BCL6), Primary Mediastinal Large B-cell Lymphoma, Plasmablastic Lymphoma, and several other related types (confirm with trial site for the full list)
- People whose lymphoma developed newly from a previously slow-growing (indolent) B-cell lymphoma
- Cohort A: People with newly diagnosed Large B-cell lymphoma who are not well enough to receive the standard full-dose chemotherapy treatment (R-CHOP or Pola-R-CHP)
- Cohort B: People with Large B-cell lymphoma whose disease has come back or stopped responding after one previous round of treatment, including those who have previously received CAR-T cell therapy
- People who are already participating in other clinical trials or studies
- People who were previously enrolled in Cohort A of this trial and whose disease has since returned or stopped responding to treatment
- People whose treatment began less than 6 months before joining the trial, with ongoing follow-up, may have their data entered into the trial retrospectively (confirm with trial site)
Who may not be able to join:
- People whose treatment began more than 6 months before joining the trial (applies to Cohort B)
- People with newly diagnosed Large B-cell lymphoma who are well enough to receive the standard full-dose chemotherapy treatment (R-CHOP or Pola-R-CHP) (applies to Cohort A)
- People whose lymphoma has spread to the central nervous system (brain or spinal cord)
- People whose lymphoma is linked to immune system problems or suppression, such as lymphomas that developed after an organ transplant (Post-Transplant Lymphoproliferative Disorders)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Primary Endpoints (Cohorts A and B)- Progression Free Survival at 12 months (PFS12):
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.